Kinetics of IL-6 Production Defines T Effector Cell Responsiveness to Regulatory T Cells in Multiple Sclerosis
Overview
Authors
Affiliations
In multiple sclerosis (MS) autoaggressive T effector cells (Teff) are not efficiently controlled by regulatory T cells (Treg) but the underlying mechanisms are incompletely understood. Proinflammatory cytokines are key factors facilitating Teff activity in chronic inflammation. Here we investigated the influence of IL-6 on Treg sensitivity of Teff from therapy-naïve MS patients with or without active disease. Compared to healthy volunteers and independent of disease course CD4(+) and especially CD8(+) MS-Teff were insensitive against functional active Treg from healthy controls. This unresponsiveness was caused by accelerated production of IL-6, elevated IL-6 receptor expression and phosphorylation of protein kinase B (PKB)/c-Akt in MS-Teff. In a positive feedback loop, IL-6 itself induced its accelerated synthesis and enhanced phosphorylation of PKB/c-Akt that finally mediated Treg resistance. Furthermore, accelerated IL-6 release especially by CD8(+) Teff prevented control of surrounding Teff, described here as "bystander resistance". Blockade of IL-6 receptor signaling or direct inhibition of PKB/c-Akt phosphorylation restored Treg responsiveness of Teff and prevented bystander resistance. In Teff of healthy controls (HC) exogenous IL-6 also changed the kinetics of IL-6 production and induced Treg unresponsiveness. This modulation was only transient in Teff from healthy volunteers, whereas accelerated IL-6 production in MS-Teff maintained also in absence of IL-6. Hence, we showed that the kinetics of IL-6 production instead of elevated IL-6 levels defines the Teff responsiveness in early Treg-T cell communication in MS independent of their disease course and propose IL-6 and associated PKB/c-Akt activation as effective therapeutic targets for modulation of Teff activity in MS.
assessment of CAR macrophages activity against SARS-CoV-2 infection.
Amoddeo A Heliyon. 2024; 10(21):e39689.
PMID: 39524874 PMC: 11550025. DOI: 10.1016/j.heliyon.2024.e39689.
Tregs in transplantation tolerance: role and therapeutic potential.
Cassano A, Chong A, Alegre M Front Transplant. 2024; 2:1217065.
PMID: 38993904 PMC: 11235334. DOI: 10.3389/frtra.2023.1217065.
Yoshida H, Magi M, Tamai H, Kikuchi J, Yoshimoto K, Otomo K Rheumatology (Oxford). 2024; 63(9):2515-2524.
PMID: 38530780 PMC: 11371379. DOI: 10.1093/rheumatology/keae196.
Rodriguez J, De Santis Arevalo J, Dennis V, Rodriguez A, Giambartolomei G Front Immunol. 2024; 14:1343503.
PMID: 38322014 PMC: 10844513. DOI: 10.3389/fimmu.2023.1343503.
Cancer and Autoimmune Diseases as Two Sides of Chronic Inflammation and the Method of Therapy.
Rogovskii V Curr Cancer Drug Targets. 2024; 24(11):1089-1103.
PMID: 38288812 DOI: 10.2174/0115680096282480240105071638.